Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · IEX Real-Time Price · USD
6.32
-0.21 (-3.29%)
Apr 18, 2024, 4:00 PM EDT - Market closed

Company Description

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally.

The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products.

The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022.

Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Lifecore Biomedical, Inc.
Lifecore Biomedical logo
Country United States
Founded 1986
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 459
CEO James G. Hall

Contact Details

Address:
3515 Lyman Boulevard
Chaska, Minnesota 55318
United States
Phone (952) 368-4300
Website lifecore.com

Stock Details

Ticker Symbol LFCR
Exchange NASDAQ
Fiscal Year June - May
Reporting Currency USD
CIK Code 0001005286
ISIN Number US5147661046
Employer ID 94-3025618
SIC Code 2834

Key Executives

Name Position
James G. Hall Chief Executive Officer, President and Director
John D. Morberg Executive Vice President and Chief Financial Officer
Dr. Albert D. Bolles Ph.D. President of Curation Foods, Inc.
Steve W. Laninga Vice President of Operations
Dr. Kipling Thacker Ph.D. Vice President and Chief Scientist
Aaron Perlitsh Director of Internal Audit and Chief Compliance Officer
Darren M. Hieber Senior Vice President of Corporate Development and Partnerships
Kara Morley Senior Vice President of Human Resources
Jackie Q. Klecker Executive Vice President and GM
Matt Augustson Senior Vice President of Information Technology

Latest SEC Filings

Date Type Title
Apr 8, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Apr 1, 2024 8-K Current Report
Mar 26, 2024 8-K Current Report
Mar 21, 2024 8-K Current Report
Mar 20, 2024 8-K Current Report
Mar 20, 2024 10-K Annual Report
Feb 29, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 16, 2024 8-K Current Report
Feb 14, 2024 SCHEDULE 13G Filing
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals